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ABSTRACT 
Accumulating evidence indicates that miR-9-5p plays an important role in several diseases, especially tumor pro-
gression. In this study, we investigated the clinical significance and biological function of miR-9-5p in prostate 
cancer (PCa). Using quantitative real time PCR (qRT-PCR) analysis, we found miR-9-5p level was significantly 
down-regulated in PCa tissues and cell lines. The decreased miR-9-5p expression was associated with tumor size, 
preoperative PSA, Gleason score and lymph node metastasis. Kaplan-Meier survival analysis showed patients with 
low level of miR-9-5p had significantly decreased rates of overall survival (OS). Multivariate analyses showed 
that miR-9-5p was an independent predictor of PCa patients’ prognosis. Through CCK-8 and Transwell assays, 
miR-9-5p overexpression by miR-9-5p mimics transfection was demonstrated to suppress the proliferation, mi-
gration and invasion of PCa cells. Mechanistically, luciferase reporter assay, qRT-PCR and Western blot demon-
strated that Utrophin (UTRN) is a direct target of miR-9-5p in PCa cells. The status of UTRN protein in PCa 
tissues was much higher than that in adjacent tissues by immunohistochemical staining and its mRNA levels were 
inversely correlated with miR-9-5p in PCa tissues. Importantly, UTRN knockdown by siUTRN imitated the sup-
pressive effects of miR-9-5p on cell proliferation, migration and invasion in PCa. In summary, miR-9-5p might 
novel prognostic biomarker in and targeting UTRN by miR-9-5p could be potential therapeutic candidates for 
PCa. 
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INTRODUCTION 
Prostate cancer (PCa) has long been one 
of the most dangerous malignant tumors 
among males and has surpassed lung cancer 
as the most frequent cancer entity in many 
countries (Mohler et al., 2016). It is estimated 
that PCa will be projected to occur in 161,360 
men in the United States and that 26,730 will 
die from their disease in 2017 (Siegel et al., 
2017). In East Asia, there were approximately 
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122,000 incidences and 42,000 deaths (Baade 
et al., 2013). The growth of PCa is androgen-
dependent, hormone-ablation therapy with 
anti-androgens and/or androgen-deprivation 
therapies has become an important compo-
nent of the treatment (Otsuki et al., 2017). 
However, most PCa patients ultimately de-
velop a recurrent independent form (castra-
tion-resistant PCa) after a median time of 18 
months (Ko et al., 2018). In recent years, mul-
tiple studies have identified the involvement 
of microRNAs (miRNAs) in the malignant 
transformation and progression of PCa, thus, 
understanding the clinical and pathological 
implications of miRNAs in PCa may provide 
therapeutic guidance. 
MiRNAs represent a class of small, 
noncoding RNAs that regulate gene expres-
sion in many cellular processes (Balacescu et 
al., 2018). Despite the first miRNA, lin-4 was 
discovered in the worm Caenorhabdities ele-
gans (Ce), it didn’t draw much attention until 
the identification and characterization of let-
7, a novel miRNA that is required for devel-
opmental timing in Ce (Reinhart et al., 2000). 
To date, more than 2000 genes that encode 
miRNAs have been found in human genome 
(Acunzo et al., 2015). These molecules typi-
cally degrade or translationally inhibit their 
target mRNAs, including those of genes that 
involved in carcinogenesis, including cell 
proliferation, apoptosis, differentiation, and 
cell cycle progression (Shenoy and Blelloch, 
2014). miRNA-target chimeras is initiated by 
incomplementary base paring interaction be-
tween the 5’-untranslated region (UTR) of the 
miRNA and the binding sequence within the 
coding region or the 3’UTR of their mRNAs 
(Hoffman et al., 2016). miR-9-5p is a member 
of the miRNA family that has been reported 
to be primarily expressed in the central nerv-
ous system (Barbano et al., 2017). It was 
found to inhibit the transformation of fibro-
blasts into myofibroblasts through targeting 
TGBR2 and NOX4 (Fierro-Fernandez et al., 
2015). Sun et al. (2016) showed that miR-9-
5p impairs proliferation, differentiation and 
adhesion of skeletal cells. The involvement 
and the role played by miR-9-5p in breast can-
cer revealed that miR-9-5p is associated with 
hormone receptor status and patients’ survival 
(Barbano et al., 2017). However, biologic and 
clinical significance of miR-9-5p remains un-
known in PCa. 
Utrophin (UTRN) encodes a dystrophin-
related protein that shows protein sequence 
homology, size, and functional properties 
with dystrophin, and overexpression of 
UTRN enables functional of dystrophin-defi-
cient skeletal muscle (Perkins and Davies, 
2018). Integrated genomic and functional 
analyses revealed that UTRN is located at 
6q24 and capable of inducing cancer cell tans-
formation when expressed at a low level, im-
plying an antioncogenic role in multiple tu-
mors (Li et al., 2007). Whereas, Lomnytska et 
al. (2006) observed significantly increased 
expression of UTRN in plasma of ovarian and 
breast cancer patients. Recently, knockdown 
of UTRN by using lentivirus-mediated sys-
tem was found to reduce the cellular prolifer-
ation and survival in human glioma (Shen et 
al., 2016). The previous meta-analysis by 
Wang et al. (2013) identified UTRN as an 
overlapped differentially expressed gene in 
PCa and suggesting the importance of UTRN 
in tumor progression. 
In the current study, the expression of 
miR-9-5p in PCa was examined and its clini-
cal significance and correlation to overall sur-
vival were analyzed. Functional assays were 
employed to reveal the effects of miR-9-5p on 
PCa proliferation, migration and invasion in 
vitro. Using computational molecular biology 
and luciferase reporter assay, we identified 
the PCa-related gene UTRN as a direct target 
of miR-9-5p. This study on the role of miR-9-
5p/UTRN network in PCa progression will no 
doubt enrich of knowledge of PCa etiology 
and treatment. 
 
MATERIALS AND METHODS 
Patients’ and tissues’ samples 
A total of 78 pairs of fresh surgical re-
sected tumor tissues and adjacent matched tis-
sues were collected from patients with PCa, 
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who were undergone a radical prostatectomy, 
and received no chemotherapy, radiation ther-
apy or androgen-deprivation treatment in The 
Fifth Affiliated Hospital of Sun Yat-sen Uni-
versity. Collected fresh tissues were immedi-
ately frozen in liquid nitrogen and stored at -
80 °C for RNA extraction. Some clinico-
pathological characteristics for all patients, 
including tumor size, Gleason score and bio-
chemical recurrences were summarized in Ta-
ble 1. The beginning of the follow-up period 
was defined as the date of prostatectomy and 
the follow-up period lasted for five years. For 
immunohistochemistry, paraffin-embedded 
tissue sections (n= 45), including 26 PCa tis-
sues and 19 adjacent normal prostate tissues 
were obtained from The Fifth Affiliated Hos-
pital of Sun Yat-sen University. All patients 
signed the informed consent before enrolled 
in this research. The study was performed ac-
cording to the principles of the Helsinki Dec-
laration, which was approved by the Ethical 
Committee of The Fifth Affiliated Hospital of 
Sun Yat-sen University (SYU-2017-42). 
 
Cell lines and culture condition 
Human PCa cell lines (LNCaP, DU145, 
22RV1, and PC-3), normal prostate epithelial 
cell line RWPE-1 and 293T cells were pur-
chased from American Type Culture Collec-
tion (ATCC, Manassas, VA, USA). All cell 
lines were cultured in Roswell Park Memorial 
Institute (RPMI) 1640 medium (GIBCO, 
Grand Island, NY, USA) with 10 % fetal bo-
vine serum (FBS, GIBCO) and maintained in 
a humidified atmosphere containing 5 % CO2 
at 37 °C.  
 
 
 
Table 1: Association between miR-9-5p expression and clinicopathological variables of patients with 
prostate cancer 
Variable Cases (n=78) Expression of miR-9-5p P value 
Low (n=44) High (n=34) (chi-square test) 
Age    0.605 
< 60 47 24 23  
≥ 60 31 20 11  
Tumor size (cm) 
 
0.003 
< 4 43 17 26 
 
≥ 4 35 27 8  
Preoperative PSA    0.004 
< 4 ng/ml 3 1 2  
4-10 ng/ml 20 4 16  
>10 ng/ml 55 39 16  
Pathological stage 0.054 
I-II 51 21 30 
III-IV 27 23 4 
Gleason score    < 0.001 
< 7 24 7 17  
7 33 17 16  
≥ 8 21 20 1  
Lymph node  
metastasis 
   0.002 
No 68 35 33  
Yes 10 9 1  
BCR    0.061 
Negative 59 28 31  
Positive 19 16 3  
PSA, prostate-specific antigen; BCR, biochemical recurrence; BCR was described as postoperative serum PSA ≥ 0.2 ng/ml 
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Oligonucleotide transfection 
The miR-9-5p mimics (5′-CGAGCTCT-
GTGTGTGTGTGTGTGTG-3′), negative 
control (miR-NC: 5′-UUCUCCGAACGUG-
UCACGUTT-3′), small interfering RNA that 
targeted UTRN (siUTRN: 5′-CUCCAU-
UAGCUGAGUUCUAACAAG-3′) and 
scrambled siNC (5′-UGACCUCAAC-
UACAUGGUUTT-3′) were synthesized by 
Shanghai GenePharma Co., Ltd. (Shanghai, 
China). For cell transfection, LNCaP and 
DU145 were seeded in six-well plates at a 
density of 2 × 105 cells per well and cultured 
until 60–80 % confluency, followed by trans-
fection with the above oligonucleotides at a 
final concentration of 50 nM using Lipofec-
tamineTM 2000 (Invitrogen, Carlsbad, CA, 
USA) according to the manufacturer's proto-
col. 
 
Quantitative real time polymerase chain  
reaction (qRT-PCR) 
Total RNA was extracted from surgically 
resected fresh tissues and cell lines using TRI-
ZOL reagent and then reversely transcribed 
by using Superscript III kit (all from Invitro-
gen) according to the manufacturer’s instruc-
tions. For the quantification of miR-9-5p, the 
PCR amplification was performed with Taq-
Man miRNA Assay kit (Applied Biosystems, 
Foster City, CA, USA) using the primers (for-
ward: 5′-GTGCAGGGTCCGAGGT-3′ and 
reverse: 5′-GCGCTCTTTGGTTATCTAGC-
3′) on ABI Prism 7700 system (Applied Bio-
systems, USA). For UTRN mRNA, the PCR 
amplification was conducted using SYBR 
Green Real time PCR Master Mix (Takara 
Bio, Inc., Shiga, Japan) with the primers (for-
ward: 5′-CAAACACCCTCGACTTGGTT-3′ 
and reverse: 5′-TGGTGGAGCTGCTATCA-
GTG-3′) on ABI Prism 7700 system (Applied 
Biosystems, USA) according to the manufac-
turer's protocols. Each sample was analyzed 
in triplicates and the expression of miR-9-5p 
and UTRN relative to U6 and GAPDH, re-
spectively was calculated using the 2-ΔΔCt 
method. 
Cell proliferation assay 
Cell proliferation rate was determined us-
ing Cell Counting Kit-8 (CCK-8, Beyotime 
Institute of Biotechnology, Haimen, China) 
following the instructions of manufacturer. In 
brief, PCa cells were seeded at a density of 
3,000/well in 96-well plates and incubated 
with 10 µl CCK-8 reagent at the indicated 
time points (24, 48, 96 and 120 h, respec-
tively). The absorbance value was measured 
at 450 nm using a Microplate Reader (Bio-
Rad, Hercules, CA). The experiments were 
independently performed in triplicate. 
 
Cell migration and invasion assays 
The Transwell chambers (pore size, 8.0 
μm, EMD Millipore, Billerica, MA, USA) 
were used to assess cell migration and inva-
sion ability without or with 10 % Matrigel 
(BD Biosciences), respectively. Briefly, ap-
proximately 1.5×104 cells in 200 uL of serum-
free medium were added to in the upper 
chamber of the Transwell chamber, while 500 
µl medium containing 10 % FBS used as an 
attractant was added to the lower chamber. 
After 24 h incubation at 37 °C, the cells that 
had migrated or invaded in the lower side of 
the chamber were fixed in 4 % paraformalde-
hyde and stained with 0.2 % crystal violet 
(Sigma-Aldrich Co.) at room temperature. Fi-
nally, stained cells in five random high-power 
microscopic fields (200× magnification) were 
photographed and counted under a light mi-
croscope (Olympus Corporation). The exper-
iments were independently performed in trip-
licate. 
 
Target prediction and luciferase reporter 
assay 
The online algorithm TargetScan 
(http://www.targetscan.org) and miRanda 
(http://www.microrna.org) were used to pre-
dict the targets of miR-9-5p. For luciferase re-
porter assay, a wild-type 3′-untranslated re-
gion UTRN (WT-3’UTR-UTRN) containing 
the putative miR-9-5p binding sequence and a 
mutant UTRN (MUT-3′-UTR-UTRN) spe-
cific for miR-9-5p binding site were amplified 
and inserted into the psi-CHECK2 vector 
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(Promega Corporation, Madison, WI, USA) 
to generate WT-UTRN and MUT-UTRN re-
porter vectors, respectively. The 293T cells at 
a density of 1×104 cells/well were seeded in 
96-well plates and cultured overnight, fol-
lowed by co-transfection with miR-9-5p 
mimics or miR-NC (40 nM) and reporter vec-
tors (0.3 μg/mL) using LipofectamineTM 
2000. After 48 h transfection, the cells were 
harvested and relative luciferase activity was 
calculated using the Dual-Luciferase Re-
porter Assay System (Promega Corporation). 
The experiments were independently per-
formed in triplicate. 
 
Western blot 
Total protein was extracted using RIPA 
buffer (Cell Signaling Technology, Inc., Dan-
vers, MA, USA) and quantified by BCA Pro-
tein Assay Kit (Thermo Scientific, Rockford, 
IL, USA). Equal amounts of protein (30 μg) 
were separated by 10 % sodium dodecyl sul-
fate polyacrylamide gel electrophoresis 
(SDS-PAGE) and transferred to PVDF mem-
branes (EMD Millipore, Billerica, MA, USA) 
in semi-dry Trans-Blot Turbo system (Bio-
Rad). Membranes were blocked 5 % non-fat 
milk in PBS containing 0.5 % Tween-20 
(PBST) for 1 h and subsequently incubated 
overnight at 4 °C with specific primary anti-
bodies against UTRN (1:500, ab159789, 
Abcam, Cambridge, UK) and GAPDH 
(1:5000, ab9482, Abcam) served as a loading 
control. After being washed with PBST, the 
membranes were incubated with horse radish 
peroxidase (HRP)-coupled secondary anti-
bodies (1:5000, Santa Cruz, CA, USA) and 
visualized by enhanced chemiluminescence 
(Thermo Scientific). 
 
Immunohistochemical (IHC) staining 
IHC staining was performed to detect the 
expression of UTRN in PCa and adjacent tis-
sues according to a previous report (Wu et al., 
2013). Briefly, the paraffin-embedded sec-
tions were cut into 4-µm thickness slides and 
deparaffinized with xylene. After rehydration 
with gradient concentrations of ethanol, mi-
crowave antigen retrieval was performed with 
EDTA buffer (pH = 8.0) for 30 min. Subse-
quently, endogenous peroxidase was blocked 
in 0.2 % H2O2 and the slides were incubated 
with primary antibody against UTRN (1:500, 
ab159789, Abcam) overnight at 4 °C, fol-
lowed by incubation with HRP-conjugated 
secondary antibody for 30 min at 37 °C. The 
IHC staining of UTRN was independently 
evaluated by two experienced pathologists. 
The staining percentage with a score of 0–4 
was assigned (0, 0-5 %; 1, 6–20 %; 2, 21–
60 %; 3, 61–75 %; or 4, 76–100 %). The 
staining intensity was graded as 0 (no stain-
ing), 1 (weak), 2 (moderate) and 3 (strong 
staining). The sum of the two scores of 0-1, 2-
4 and 5-6 were considered to be weak staining 
(-+), moderate staining (+) and strong staining 
(+ +), respectively according to a previous re-
port (Schuster et al., 2012). 
 
Statistical analysis 
Statistical analysis was performed using 
SPSS 19.0 (SPSS Inc., Chicago, IL, USA). 
The unpaired t test was used to compare tu-
mor and healthy tissues. Box plots and 
Shapiro-Wilk (W test) were used to assure our 
data were normally distributed. The Bartlett 
test was used for homogeneous variances. 
The t test checks for equality of the means re-
quiring normality (tested by Shapiro-Wilk 
test) and homogeneity of the variances (tested 
by Bartlett test). The Welch t tests can be used 
in case non-homogeneous variances. The as-
sociation between miR-9-5p expression and 
the categorical variables was assessed by us-
ing χ2 tests. Survival analysis was conducted 
with the Kaplan-Meier method with the log-
rank test. The independent prognostic value 
of miR-9-5p expression was evaluated using 
univariate and multivariate (covariable in-
cludes tumor size, Preoperative PSA, Gleason 
score) Cox regression models. The differ-
ences between two groups were assessed by 
2-tailed Student t test and multiple groups us-
ing one-way or two-way analysis of variance 
followed by a post-hoc Bonferroni test (fac-
tors include different transfections, cell lines 
and luciferase constructs). Values of p < 0.05 
were considered statistically significant. 
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RESULTS 
Down-regulation of miR-9-5p was closely 
associated with worse clinical outcomes in 
human PCa 
To investigate the biological function of 
miR-9-5p in PCa, qRT-PCR analysis was first 
performed to determine the expression of 
miR-9-5p in PCa tissues and adjacent prostate 
tissues. As shown in Figure 1A, miR-9-5p 
levels were found to be significantly down-
regulated in 78 pairs of PCa tissues compared 
with matched adjacent tissues. At the same 
time, we compared the expression of miR-9-
5p in PCa with different Gleason Scores and 
found lower levels of miR-9-5p were mostly 
observed in PCa tissues with higher Gleason 
score (Figure 1B). Subsequently, total 78 PCa 
tissues were divided into high- (n = 34) and 
low-miR-9-5p (n = 44) expression group 
based on the median value of miR-9-5p levels 
to investigate the clinical significance of miR-
9-5p in PCa patients. As shown in Table 1, 
down-regulated miR-9-5p was significantly 
correlated with tumor size (p = 0.003), pre-
operative PSA (p = 0.004), Gleason score (p 
< 0.001) and lymph node metastasis (p = 
0.002). Kaplan–Meier analyses revealed that 
PCa patients with higher levels of miR-9-5p 
had longer overall survival rate than those 
with lower levels of miR-9-5p (Figure 1C, p 
= 0.0035). Importantly, multivariate analyses 
showed that miR-9-5p (HR = 3.05, 95 % CI: 
2.97-3.55; p = 0.004) was an independent pre-
dictor of PCa patients’ prognosis (Table 2). 
Taken together, these results suggest that de-
creased expression of miR-9-5p indicates a 
poor prognosis and might be a potential bi-
omarker for PCa patients. 
 
 
Figure 1: Down-regulated expression level of miR-9-5p was correlated with PCa progression. (A) The 
expression levels of miR-9-5p were determined in 78 pairs of PCa tissues and matched adjacent tissues 
using qRT-PCR analysis. (B) MiR‐9-5p expression was evaluated in PCa tissues with low, moderate 
and high Gleason Score, respectively. (C) Kaplan-Meier analysis of overall survival rate for patients with 
PCa with low and high serum miR-9-5p levels. 
 
 
Table 2: Univariate and multivariate analysis using Cox proportional hazard regression model for five-
year survival rate in PCa patients 
Variable HR (95 % CI) P-value 
Univariate   
Age 2.35 (1.86-2.86) 0.532 
Tumor size (cm) 1.02 (0.86-1.86) 0.022 
Preoperative PSA 2.67 (2.16-2.98) 0.004 
Pathological stage 4.02 (3.75-5.01) 0.083 
Gleason score 2.89 (2.46-3.16) 0.021 
Lymph node metastasis 1.65 (1.16-2.24) 0.103 
BCR 2.75 (1.98-3.26) 0.062 
Multivariate   
Tumor size (cm) 3.15 (2.96-3.47) 0.051 
Preoperative PSA 2.46 (1.96-2.99) 0.014 
Gleason score 1.59 (1.26-2.34) 0.002 
Tissue miR-9-5p expression 3.05 (2.97-3.55) 0.006 
HR: hazard ratio; CI: confidence interval
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miR-9-5p overexpression inhibited the  
proliferation, migration and invasion of 
PCa cells 
To better perform the in vitro experi-
ments, the expression of miR-9-5p was ana-
lyzed in several PCa cell lines using qRT-
PCR analysis. As depicted in Figure 2A, the 
expression of miR-9-5p was significantly de-
creased in PCa cell lines (LNCaP, DU145, 
22RV1, and PC-3), in comparison with nor-
mal prostate epithelial cell line RWPE-1 (p < 
0.01, p < 0.001). As the miR-9-5p level was 
lowest in LNCaP and DU145 cells, we thus 
chose them for gain-of-function experiments. 
As demonstrated in Figure 2B, miR-9-5p 
mimics transfection significantly increased 
the expression level of miR-9-5p in both 
LNCaP and DU145 cells compared with miR-
NC transfection (p < 0.001). The CCK-8 as-
say showed that miR-9-5p overexpression 
significantly suppressed cell proliferation of 
LNCaP (p < 0.001) and DU145 (p < 0.01, p < 
0.001) cells at the indicated time points (Fig-
ure 2C). The relentless PCa cell invasion is 
the major cause resulting in poor outcome and 
death of the patients. Next, we examined 
whether miR-9-5p affected cell migration and 
invasion in PCa using Transwell assays. As 
shown in Figure 2D, miR-9-5p overexpres-
sion significantly decreased the migratory 
cells from 68.3 ± 3.5 to 22.0 ± 3.6 in LNCaP 
cells and from 50.7 ± 4.9 to 7.0 ± 1.6 in 
DU145 cells (p < 0.001). Consistently, trans-
fection with the miR-9-5p mimics markedly 
decreased invasion ability of LNCaP (15.7 ± 
2.5 vs. 56.3 ± 2.5, p < 0.001) and DU145 (10.0 
± 2.6 vs. 41.7 ± 2.9, p < 0.001) cells compared 
to transfection with miR-NC (Figure 2E). 
These data indicate that miR-9-5p might be an 
effective inhibitor of cell proliferation, migra-
tion and invasion in PCa cells. 
 
UTRN might be a direct target of miR-9-5p 
in PCa 
Based on the TargetScan and miRanda 
software, potential binding sites of miR-9-5p 
at positions 160-166 in the 3’UTR of UTRN 
were predicted and shown in Figure 3A. 
Meanwhile, luciferase reporter assay was 
used to confirm this prediction and the results 
showed that the luciferase activity of the WT 
UTRN 3’UTR was significantly inhibited by 
miR-9-5p mimics transfection, whereas the  
 
 
 
Figure 2: miR-9-5p suppressed cell proliferation, migration and invasion in PCa cells. (A) The 
expression levels of miR-9-5p were determined in PCa cell lines (LNCaP, DU145, 22RV1, and PC-3) 
and normal prostate epithelial cell line RWPE-1 using qRT-PCR analysis. (B) The significantly elevated 
expression of miR-9-5p in LNCaP and DU145 cells transfected with miR-9-5p mimics. (C) Relative cell 
proliferation rate was assessed in LNCaP and DU145 cells using CCK-8 assay. Representative images 
(left panel) and statistical analysis (right panel) of the (D) migratory and (E) invasive cell number of 
LNCaP and DU145 cells transfected with miR-9-5p mimics are presented (magnification, ×200). Data 
are presented as the mean ± SD from at least three independent experiments. **p < 0.01, ***p < 0.001
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luciferase activity of the mutant UTRN 
3’UTR was not affected (Figure 3B, p < 0.01). 
To illustrate whether the endogenous miR-9-
5p can directly regulate the expression of 
UTRN, the changes of UTRN was monitored 
in LNCaP and DU145 cells after miR-9-5p 
mimics transfection. Using qRT-PCR (Figure 
3C, p < 0.001) and Western blot analysis (Fig-
ure 3D), we found the mRNA and protein of 
UTRN were significantly decreased in 
LNCaP and DU145 cell transfected with miR-
9-5p mimics, as compared with miR-NC. 
These results revealed that miR-9-5p directly 
regulated UTRN expression in PCa cells by 
targeting its 3’UTR. 
 
UTRN was highly expressed in PCa tissues 
and negatively correlated with miR-9-5p 
The expression of UTRN protein was ex-
amined in 26 paraffin-embedded PCa samples 
and 19 normal prostate samples by IHC stain-
ing analysis. As shown in Figure 4A, three de-
grees of UTRN expression intensity were de-
scribed by representative photomicrographs. 
Further statistical analysis demonstrated that 
most of paraffin-embedded PCa tissues 
showed strong and moderate UTRN staining, 
while weak UTRN staining was mainly ob-
served in adjacent normal tissues (Figure 4B, 
p < 0.001). In addition, we analyzed the ex-
pression of UTRN mRNA in 78 pairs of PCa 
tissues and matched adjacent tissues using 
qRT-PCR. In agreement with the above re-
sults, PCa tissues displayed remarkably 
higher levels of UTRN mRNA compared with 
those in adjacent prostate tissues (Figure 4C, 
p < 0.001). Moreover, Spearman correlation 
analysis demonstrated the expression of 
UTRN was negatively correlated with miR-9-
5p expression levels in PCa tissues (Figure 
4D, r = -0.2711, p = 0.0163). 
 
UTRN knockdown imitated the suppressive 
effects of miR-9-5p on cell proliferation, 
migration and invasion in PCa cells 
Next, we explored the biological function 
of UTRN in PCa cells by performing loss-of-
function assays. As shown in Figure 5A, the 
expression of UTRN at mRNA and protein 
levels was both significantly down-regulated 
in LNCaP cells after siUTRN transfection, in 
comparison with siNC transfection, as deter-
mined by qRT-PCR (p < 0.001) and Western 
blot analysis. Cell proliferation was assessed 
via a CCK-8 assay. The data suggested that  
 
Figure 3: miR-9-5p down-regulated the expression of UTRN by targeting its 3’UTR. (A) The seed 
sequences for miR-9-5p in the 3’UTR of UTRN were displayed. (B) Luciferase reporter assay was per-
formed 48 h after co-transfection in 293T cells with WT UTRN or MUT UTRN vectors together with miR-
9-5p mimics or miR-NC. (C) QRT-PCR revealed the effects of miR-9-5p mimics on the expression level 
of UTRN mRNA in LNCaP and DU145 cells. (D) Western blot analysis revealed the effects of miR-9-5p 
mimics on the expression level of UTRN protein in LNCaP and DU145 cells. Data are presented as the 
mean ± SD from at least three independent experiments. **p < 0.01, ***p < 0.001
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Figure 4: Upregulated UTRN levels were negatively correlated with miR-9-5p in PCa tissues. (A) 
Representative images of immunohistochemistry staining of UTRN in PCa and adjacent tissues (-+, 
weak staining, + moderate staining, ++ strong staining); (B) Statistical analysis of UTRN protein expres-
sion by immunohistochemistry; p < 0.001; (C) Relative UTRN mRNA levels in PCa tissues and matched 
adjacent tissues were measured using qRT-PCR. ***p < 0.001 compared with adjacent tissues; (D) The 
association between UTRN mRNA and miR-9-5p expression was evaluated using Spearman correlation 
analysis in PCa tissues. r = −0.2711, p = 0.0163 
 
UTRN knockdown significantly attenuated 
cell proliferation of LNCAP cells (Figure 5B, 
p < 0.001). Additionally, transwell assay (Fig-
ure 5C, p < 0.001) revealed a significant de-
crease in migratory and invasive cells trans-
fected with siUTRN compared with in the 
corresponding siNC in LNCaP cells. These 
findings indicated that UTRN might be a 
functional regulator in the effects of miR-9-
5p on PCa cells. 
 
DISCUSSION 
MiR-9 has been found to be expressed in 
the nervous system and originally defined as 
a versatile regulator of neurogenesis (Coolen 
et al., 2013). In recent years, miR-9 in humans 
was reported to target genes involved in mi-
croglial activation (Yao et al., 2014), fibro-
blasts transformation (Fierro-Fernandez et al., 
2015), and tumorigenesis (Wang et al., 2015). 
In this study, we observed that miR-9-5p was 
significantly decreased in PCa tissues com-
pared with adjacent tissues, and this reduction 
was obviously related to poor overall survival 
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Figure 5: UTRN knockdown presented similar effects in miR-9-5p-overpressing PCa cells. (A) 
QRT-PCR and western blot analysis of UTRN expression in LNCaP cells after transfection with siUTRN 
or siNC, respectively. (B) The cell proliferation rate of LNCaP cells after UTRN knockdown was analyzed 
by the CCK-8 assay. (C) Representative images (left panel) and statistical analysis (right panel) of the 
migratory and invasive cell number of LNCaP cells transfected with siUTRN are presented (magnifica-
tion, ×200). Data are presented as the mean ± SD from at least three independent experiments. ***p < 
0.001 
 
 
in patients with PCa. Uncontrolled cell prolif-
eration, invasion and migration: all these 
properties of a cancer cell lead to its tumor-
igenic phenotype and impact patients progno-
sis (Musa et al., 2017). Here, enforced expres-
sion of miR-9-5p inhibited these properties in 
vitro by gain-of-function experiments 
through directly binding and inhibiting the ex-
pression of UTRN. MiR-9-5p and its down-
stream target UTRN can be used as predictive 
and/or prognostic biomarkers in PCa. 
The association between miR-9-5p and 
malignant biological behaviors of tumor cells 
have already been reported in several studies. 
A growing literature supports the role of miR-
9-5p in the modulation of biological processes 
are mainly mediated by network of miRNA-
mRNA target interactions. Wang et al. (2015) 
showed that miR-9-5p is low-expressed in 
bladder cancer tissues, and treatment of BIU-
87 cells with miR-9-5p inhibitor in vitro sug-
gested that the proliferative and invasive ef-
fects of miR-9-5p were due to specific target-
ing of LASS2. In esophageal squamous cell 
carcinoma (ESCC), miR-9-5p plays a critical 
role in migration and metastasis by activating 
β-catenin pathway and inducing epithelial-
mesenchymal-transition via binding to target 
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sites in the 3’UTR region of E-cadherin (Song 
et al., 2014). Particularly, Sohn et al. (2015) 
revealed that overexpression of miR-9-5p in 
ESCC significantly correlated with clinical 
progression, lymph node metastasis, and poor 
overall survival. Similarly, a previous study 
indicates that miR-9-5p induces an aggressive 
and invasive phenotype in non-small cell lung 
cancer (NSCLC) by targeting TGFBR2 (Li et 
al., 2017). Therefore, the transcriptional reg-
ulation by miR-9-5p seems to be dependent 
on human tissues and cell types: In PCa miR-
9-5p appears to have anti-growth functions 
and predicts a good prognosis. However, it 
mainly has pro-metastasis functions and/or 
indicates a poor prognosis in many cancers, 
including bladder cancer, ESCC, and 
NSCLC. However, the capability of miR-9-
5p to act as a prognostic biomarker in PCa 
will require further exploration. 
UTRN is present as a high-molecular-
weight protein that has substantial structural 
and sequence homology to dystrophin (Keefe 
and Kardon, 2015). It is known that loss of 
dystrophin is a major risk factor for Duchenne 
muscular dystrophy, a fatal X-linked muscle-
wasting disorder (Dumont et al., 2015). 
UTRN can functionally compensate for dys-
trophin deficiency when it is upregulated in 
the myofibre (Gordon et al., 2013). In recent 
years, behavior and effects of UTRN in mul-
tiple biological processes has attracted much 
attention. In this study, qRT-PCR and im-
munohistochemistry staining revealed that 
UTRN is amplified in PCa tissues, indicating 
that UTRN is an oncogene in PCa. In a fur-
ther, inhibition of UTRN expression was 
found to attenuate the capabilities of PCa cells 
proliferation, migration and invasion. Inter-
estingly, in pancreatic endocrine tumors 
(PETs) cells, UTRN was shown to be local-
ized to cell membranes, and the membranous 
UTRN localization correlated with short sur-
vival of PETs patients (Chang et al., 2007). 
Therefore, negative regulation of UTRN by 
miR-9-5p may not be at all but at least par-
tially responsible for poor prognosis of PCa 
patients with low serum miR-9-5p levels. In a 
previous study, the proliferation of muscle-
derived stem cells (MDSCs) was shown to be 
significantly  decreased in double dys-
trphin/UTRN deficient mice compared to that 
isolated from mice with dystrophin deficient 
but UTRN expressing (Sohn et al., 2015). 
What’s more, Shen et al. (2016) demonstrated 
that knockdown of UTRN suppressed glioma 
cells proliferation through regulation of cell 
cycle distribution. Ntantie et al. (2018) 
showed that TAPP2 links phosphoinositide 3-
kinase signaling and interaction with UTRN 
to promote the leukemia B-cell adhesion. Im-
portantly, focal adhesion formation is known 
to play a pivotal role in migration, invasion 
and growth of malignant tumor cells. Despite 
the role of UTRN is poorly understood and 
rarely investigated directly, however, the mo-
lecular biologic feature of miR-9-5p/UTRN 
axis in PCa will enrich this field. The molec-
ular mechanisms downstream of miR-9-
5p/UTRN axis still need further investigation. 
Our findings revealed that miR-9-5p may 
be useful as a novel prognostic biomarker in 
PCa and play a critical role in proliferation, 
migration and invasion though targeting 
UTRN. Restoration of miR-9-5p and down-
regulation of UTRN may represent a potential 
therapeutic for the treatment of PCa. 
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